Arcus Biosciences, Inc. (RCUS) income statement
RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30123% above fair value
$15.76−0.63 (-3.84%)
Close on Nov 18, 2026Market cap $2.01BP/E –Yield –
Arcus Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -415.4%
- Net margin
- -393.2%
- Return on equity, FY2025
- -63.3%
Financial strength
- Current ratio
- 3.82
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 75.8%
Valuation
- P/E ratio
- –
- Price to sales
- 17.15
- Price to book
- 4.32
- Dividend yield
- –
See a number that looks wrong?